Metabolic Defects in Type 2 Diabetes

Slide 1 · Metabolic Defects in Type 2 Diabetes

Insulin resistance • β-cell dysfunction • metabolic feedback

A mechanism-focused pathology lecture

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning outcomes: Connect mechanisms with glycemia

Distinguish insulin resistance from inadequate β-cell compensation.

Explain the glucose and lipid consequences in liver, muscle and fat.

Trace obesity-associated lipotoxic and inflammatory pathways.

Explain why hyperglycemia eventually emerges despite early hyperinsulinemia.

Slide 3 · Two indispensable abnormalities

Insulin resistance

β-cell dysfunction

Target tissues respond inadequately to insulin

Insulin secretion becomes insufficient for demand

Dominant sites: Liver, muscle, adipose tissue

Initially may be compensatory hyperfunction

Usually appears before overt hyperglycemia

Required for progression to overt T2D

Slide 4 · Disease evolution: Resistance precedes hyperglycemia

Insulin resistance

Reduced tissue response to insulin

β-cell compensation

Higher secretory drive and circulating insulin

Failure to adapt

Insulin output becomes inadequate for demand

Hyperglycemia

Sustained elevation in blood glucose

This is a conceptual sequence, not a quantitative time course.

Slide 5 · Early compensation can preserve normal glucose

Tissues become less responsive while β cells initially increase insulin release.

Compensatory hyperinsulinemia partly offsets the tissue defect.

Glucose tolerance may remain normal or become impaired before overt diabetes.

Slide 6 · Overt T2D reflects failure of adaptation

The insulin requirement rises as resistance persists.

β-cell secretory capacity eventually fails to match the requirement.

Relative insulin deficiency permits chronic hyperglycemia.

Slide 7 · The compensatory transition is mechanistically important

Resistant tissues

More insulin needed for metabolic effect

Compensated islets

Insulin secretion rises

Limited reserve

Secretory demand cannot be sustained

Diabetes

Glycemia rises progressively

A high insulin concentration need not imply adequate insulin action.

Slide 8 · Insulin resistance is distributed across three tissues

INSULIN RESISTANCE

Diminished normal response to insulin

Liver

Endogenous glucose output inadequately suppressed

Skeletal muscle

Meal-related glucose uptake and glycogen synthesis impaired

Adipose tissue

Triglyceride breakdown inadequately suppressed

Different tissue defects converge on disordered glucose homeostasis.

Slide 9 · The liver: Insulin normally restrains glucose output

The liver generates endogenous glucose, including through gluconeogenesis.

Insulin normally suppresses this glucose-producing activity.

Fasting glucose depends partly on whether this suppression is effective.

Slide 10 · Hepatic resistance explains elevated fasting glucose

Impaired insulin action

Reduced hepatic responsiveness

Incomplete suppression

Gluconeogenesis continues

Excess glucose output

Glucose enters circulation

Fasting hyperglycemia

Blood glucose remains elevated

This mechanistic pathway is explicit in the source.

Slide 11 · The muscle: Insulin facilitates glucose disposal

Skeletal muscle normally takes up circulating glucose after meals.

Insulin promotes glucose uptake and conversion to glycogen.

This tissue response reduces the postprandial glucose load.

Slide 12 · Muscle resistance explains postprandial dysglycemia

Meal

Circulating glucose rises

Impaired muscle action

Insulin response is reduced

Less uptake / storage

Glucose uptake and glycogen synthesis fall

Higher post-meal glucose

Glucose remains in blood

The source explicitly links muscle defects to postprandial hyperglycemia.

Slide 13 · Adipose tissue: Insulin suppresses triglyceride breakdown

Insulin normally restrains hormone-sensitive lipase activity.

This reduces triglyceride breakdown within adipocytes.

When adipose insulin action is weak, more free fatty acids enter blood.

Slide 14 · Adipose resistance increases circulating free fatty acids

Impaired insulin action

Anti-lipolytic signal is weakened

Lipase activity persists

Stored triglycerides undergo breakdown

FFAs increase

More fatty acid enters plasma

Other tissues affected

Metabolic signaling is further perturbed

FFAs = free fatty acids; Source describes lipolysis as mediator of peripheral and islet dysfunction.

Slide 15 · A tissue-by-tissue account of the metabolic defects

Tissue

Action normally promoted by insulin

Result of resistance

Liver

Suppression of gluconeogenesis

Persistent endogenous glucose production

Skeletal muscle

Glucose uptake and glycogen formation

Postprandial glucose remains elevated

Adipose tissue

Inhibition of hormone-sensitive lipolysis

Free fatty acids increase in circulation

Slide 16 · Fasting and post-meal hyperglycemia

Fasting state

Post-meal state

Failure to suppress hepatic glucose production

Skeletal muscle removes less circulating glucose

Endogenous glucose output persists

Glycogen synthesis is reduced

Hepatic insulin resistance is central

Muscle insulin resistance is central

Slide 17 · Insulin signaling begins with receptor phosphorylation

Insulin receptor signaling normally depends on regulated phosphorylation.

Reduced tyrosine phosphorylation of insulin receptors is reported in resistant tissues.

The weakened signal impairs downstream metabolic responses.

Slide 18 · IRS defects compromise the downstream insulin signal

Insulin receptor

Reduced tyrosine phosphorylation

IRS proteins

Reduced tyrosine phosphorylation

Signaling efficiency

Attenuated insulin response

Cellular effect

Lower glucose transport response

IRS = insulin receptor substrate proteins.

Slide 19 · GLUT4 translocation is a key skeletal-muscle endpoint

The amount of GLUT4 at the cell surface helps determine glucose uptake.

Impaired insulin signaling reduces surface GLUT4 availability.

Consequently, skeletal muscle responds less effectively to circulating insulin.

Slide 20 · Exercise can improve a defined insulin-response step

Exercise

Physical muscle activity

GLUT4 translocation

More transporter reaches plasma membrane

Greater glucose entry

Muscle uptake is facilitated

Improved sensitivity

Glycemic handling improves

Text attributes part of the exercise effect to GLUT4 translocation; Exact quantitative benefit not provided.

Slide 21 · Receptor signal versus tissue-level phenotype

Molecular abnormality

Metabolic expression

Reduced receptor / IRS tyrosine phosphorylation

Muscle glucose uptake decreases

Less effective GLUT4 recruitment at the surface

Hepatic glucose suppression fails

Impaired downstream signaling

Adipose lipolysis is less inhibited

Slide 22 · Obesity is a major determinant of insulin resistance

Among acquired influences, obesity is emphasized as particularly important.

Diabetes risk rises with increasing adiposity.

Body-fat distribution modifies risk beyond total body size.

Slide 23 · Why body mass index is an imperfect proxy

BMI estimates overall body size rather than the location of fat.

Two people with comparable BMI may have different fat distributions.

The metabolic consequences of abdominal and peripheral adiposity differ.

Slide 24 · Visceral and subcutaneous adiposity

Central / visceral pattern

Peripheral / subcutaneous pattern

Stronger association with insulin resistance

Comparatively weaker association with resistance

Greater lipolytic activity described

May confer relative metabolic protection

Free-fatty-acid burden tends to be greater

Protection is not absolute

Slide 25 · Visceral adiposity matters without overt obesity

An apparently nonobese phenotype does not exclude excess visceral fat.

The source highlights this pattern in some Asian and Middle Eastern populations.

Body composition can therefore be more informative than BMI alone.

Slide 26 · Central adiposity changes lipid flux

Visceral fat

More lipolytically active compartment

Fatty acid release

Higher circulating FFA exposure

Ectopic tissue effects

Adverse signaling and substrate use

Insulin resistance

Glucose handling deteriorates

Qualitative pathway; The source discusses inverse FFA/insulin sensitivity association.

Slide 27 · FFA exposure correlates inversely with insulin sensitivity

Fasting plasma FFAs are inversely associated with insulin sensitivity.

Cross-sectional association does not, on its own, prove causation.

The mechanistic evidence provides biological plausibility.

Slide 28 · Excess fatty acids can exceed oxidation capacity

A high fatty-acid supply increases the burden of intracellular lipid handling.

When oxidative pathways are overwhelmed, lipid intermediates accumulate.

The accumulated intermediates can interfere with metabolic signaling.

Slide 29 · Lipid intermediates link FFAs to cellular dysfunction

Excess intracellular fatty acids

Diacylglycerol

DAG accumulation

Phospholipids

Altered intracellular lipid pool

Sphingolipids

Including ceramides

The listed intermediates are source examples; Relative concentrations are not asserted.

Slide 30 · Lipotoxic metabolites suppress effective signaling

FFA excess

Elevated lipid substrate supply

Intracellular metabolites

DAG, ceramides and other species

Signal attenuation

Insulin response is compromised

Resistance worsens

Glucose use becomes less effective

Specific molecular intermediates are those named excerpt.

Slide 31 · Fatty acids and glucose compete as oxidative substrates

A higher fatty-acid supply favors the use of fatty acids as fuel.

Competition with glucose for oxidation.

This competition can exacerbate reduced glucose utilization.

Slide 32 · Hepatic PEPCK links signaling to glucose production

Insulin action falls

Hepatic inhibitory control weakens

PEPCK activity

Less restrained in the cited mechanism

Gluconeogenesis

Glucose synthesis is enhanced

Fasting glucose

Circulating glucose rises

Phosphoenolpyruvate carboxykinase (PEPCK) as a key regulated step; No claim it is the first enzymatic step.

Slide 33 · Adipose tissue is an endocrine organ

Adipocytes store energy and secrete circulating signaling proteins.

These secreted molecules are termed adipokines or adipose cytokines.

Some adipokines favor hyperglycemia; Others enhance insulin sensitivity.

Slide 34 · Adipokine effects are not uniformly harmful

Insulin-sensitizing signals

Hyperglycemia-promoting signals

Adiponectin is the principal named example

Other adipokines can promote dysglycemia

Supports peripheral insulin sensitivity

Net adipose output depends on metabolic state

Can contribute to lower blood glucose

The excerpt does not enumerate individual harmful adipokines

Slide 35 · Reduced adiponectin contributes to insulin resistance

Obesity

Adipose endocrine state changes

Adiponectin

Circulating concentration decreases

Peripheral tissues

Less insulin-sensitizing action

Metabolic effect

Insulin resistance increases

Some adiponectin effect to improved peripheral insulin sensitivity.

Slide 36 · Nutrient overload can promote sterile inflammation

FFAs and glucose are metabolic triggers for proinflammatory responses.

The ensuing cytokine milieu impairs insulin action.

Islet dysfunction can occur alongside peripheral resistance.

Slide 37 · The inflammasome provides a mechanistic bridge

Excess FFAs

Macrophages and β cells exposed

Inflammasome

Cytoplasmic complex is activated

IL-1β secretion

Proinflammatory cytokine is released

Broader inflammation

Other cytokines are induced

Robbins specifies inflammasome activation and IL-1β release; Pathway presented conceptually.

Slide 38 · IL-1β amplifies the cytokine environment

Inflammasome activation is linked to secretion of IL-1β.

IL-1β promotes additional cytokine secretion in several cellular compartments.

The combined inflammatory environment can worsen tissue insulin resistance.

Slide 39 · FFA-driven resistance has direct and indirect routes

Elevated free fatty acids

Direct tissue effect

Lipid intermediates impair insulin signaling

Inflammatory route

Cytokine production further attenuates insulin action

Two converging mechanisms are explicit.

Slide 40 · Inflammation also affects the pancreatic islet

Islet β cells can respond to excess FFAs with inflammatory activation.

The inflammatory milieu contributes to secretory dysfunction.

Peripheral resistance and reduced insulin output therefore reinforce each other.

Slide 41 · High circulating FFAs can cause hepatic steatosis

FFA exposure

Liver receives excess lipid substrate

Hepatocytes

Intracellular triglyceride accumulates

Steatosis

Fat accumulates in liver cells

Metabolic context

Frequently accompanies T2D / metabolic syndrome

Liver steatosis, not any particular histologic specimen, is described; Schematic only.

Slide 42 · Steatotic liver disease spans different injury states

Steatosis without injury

Steatohepatitis

Excess intrahepatocellular fat

Steatosis with hepatocyte injury

No liver-injury evidence described

Inflammatory reaction accompanies injury

Metabolic dysfunction context may be present

Fibrosis may or may not be present

Slide 43 · MASLD is a metabolic correlate, not a glucose mechanism alone

Hepatic fat accumulation is common in T2D and metabolic syndrome.

The spectrum includes steatosis and steatohepatitis.

Hepatic insulin resistance and hepatic steatosis are related but not identical findings.

Slide 44 · β-cell dysfunction is essential for overt T2D

Resistance alone can produce impaired glucose tolerance.

Overt diabetes emerges when insulin secretion cannot meet tissue demand.

This requirement distinguishes β-cell failure from resistance as an isolated lesion.

Slide 45 · The β-cell response changes with disease stage

Earlier stage

Later stage

Insulin secretory function rises

Adaptation becomes insufficient

Compensatory hyperinsulinemia develops

Relative insulin deficiency develops

Euglycemia may be preserved

Chronic hyperglycemia follows

Slide 46 · Relative insulin deficiency is contextual

Absolute insulin may still be detectable or substantial.

For the prevailing resistance and glycemia, however, output is inadequate.

Clinical dysfunction depends on supply relative to metabolic requirement.

Slide 47 · β-cell lipotoxicity links excess FFAs to secretion failure

FFA excess

Sustained nutrient oversupply

Islet exposure

Lipotoxic influences accumulate

β-cell response

Insulin release is attenuated

Diabetes risk

Compensation becomes inadequate

Lipotoxicity is a mechanism implicated by Robbins; The excerpt does not give a single indispensable molecular intermediate for the islet.

Slide 48 · Glucotoxicity creates a second pressure on β cells

Hyperglycemia

Chronic glucose elevation

β-cell stress

Glucose excess contributes to dysfunction

Lower effective secretion

Insulin is insufficient for demand

Feedback

Hyperglycemia persists

Glucotoxicity as a factor; Detailed molecular intermediates not specified.

Slide 49 · An abnormal incretin effect may impair insulin output

GIP and GLP-1 are gut-derived hormones that promote insulin release.

Disturbance of the incretin effect among β-cell defects.

The supplied excerpt does not establish a uniform defect in hormone secretion for all T2D.

Slide 50 · Islet amyloid is associated with long-standing T2D

Amyloid accumulation in pancreatic islets is a characteristic morphologic association.

It is typically considered in the context of chronic β-cell dysfunction.

The source cautions that its causal status is uncertain.

Slide 51 · Islet amyloid: Observation versus interpretation

Established observation

Causal uncertainty

Characteristic in long-standing T2D

May accompany progressive β-cell impairment

Often found in examined diabetic islets

The source does not establish cause versus effect

Represents an islet morphologic correlate

Do not teach amyloid as the sole origin of β-cell failure

Slide 52 · Genetic variation can affect secretory vulnerability

Many risk-associated polymorphisms involve pathways governing insulin release.

Genetic predisposition can influence capacity for β-cell adaptation.

Sporadic T2D remains a complex interaction of genetic and acquired factors.

Slide 53 · Factors implicated in β-cell dysfunction

β-cell dysfunction in T2D

Excess FFAs

Lipotoxicity

Glucose excess

Glucotoxicity

Gut signals

Abnormal incretin effect

Islet amyloid

Characteristic association

Genetic factors

Secretory susceptibility

Islet amyloid is associated with T2D; A causal role is unconfirmed.

Slide 54 · Insulin resistance and β-cell failure reinforce one another

Chronic metabolic stress

Peripheral resistance

Less glucose disposal and weaker suppression of output

β-cell limitation

Insulin secretion inadequate for prevailing demand

Sustained glucose excess

Glucotoxic pressure on β-cell performance

Conceptual feedback synthesis supported by tissue mechanisms and named glucotoxicity.

Slide 55 · A stage model for teaching the evolution of T2D

Predisposition

Adiposity, inherited susceptibility and context

Resistance

Liver, muscle and adipose action impaired

Compensation

Insulin secretion increases

Decompensation

Relative deficiency and hyperglycemia

Conceptual stages; No clinical diagnostic cutoffs or precise times asserted.

Slide 56 · T2D inflammation is not equivalent to T1D autoimmunity

T2D mechanism emphasized

T1D mechanism contrasted

Insulin resistance plus β-cell dysfunction

Immune-mediated β-cell destruction

Nutrient-associated inflammatory signals

Different upstream pathogenesis

No established autoimmune basis

Not the topic of this lecture

Slide 57 · Clinicopathologic exercise: Elevated fasting glucose

Clinical observation

A person with central adiposity has elevated fasting glucose on repeated assessment.

Mechanistic interpretation

Which organ defect most directly explains fasting elevation?

Why?

Resistance to hepatic insulin action impairs suppression of endogenous glucose production. The liver continues to contribute glucose during fasting.

Slide 58 · Clinicopathologic exercise: Exaggerated meal response

Clinical observation

An insulin-resistant person has a greater-than-expected glycemic rise after a meal.

Mechanistic interpretation

Which tissue response is deficient?

Why?

Skeletal-muscle glucose uptake and glycogen synthesis are not adequately stimulated by insulin. Post-meal glucose disposal is impaired.

Slide 59 · Clinicopathologic exercise: Size alone is misleading

Clinical observation

An adult has no overt obesity by general appearance but has disproportionate visceral adiposity.

Mechanistic interpretation

Does a normal-looking body size exclude insulin resistance?

Why?

No. Visceral fat distribution is metabolically important, and BMI alone does not capture its location.

Slide 60 · Clinicopathologic exercise: High insulin with dysglycemia

Clinical observation

An individual has insulin resistance and increased circulating insulin but already shows impaired glucose tolerance.

Mechanistic interpretation

How can insulin be elevated and still be inadequate?

Why?

Tissue responsiveness is reduced, so the amount of insulin required for normal glucose handling has increased.

Slide 61 · Clinicopathologic exercise: Transition to overt diabetes

Clinical observation

After years of insulin resistance, glycemia becomes persistently elevated despite continued endogenous insulin production.

Mechanistic interpretation

Which second defect has become decisive?

Why?

β-cell output is now insufficient for metabolic requirements: Relative insulin deficiency.

Slide 62 · Mechanistic recap: Identify the causal chain

Liver: Inadequate suppression of glucose production → fasting hyperglycemia.

Muscle: Reduced uptake / glycogen storage → postprandial hyperglycemia.

Adipose tissue: Persistent lipolysis → elevated FFAs and downstream stress.

β cells: Compensation eventually becomes inadequate → sustained diabetes.

Slide 63 · Three distinctions that prevent diagnostic confusion

Insulin resistance is impaired action, not automatically absent insulin.

A high insulin concentration can coexist with inadequate metabolic effect.

Islet amyloid is associated with T2D, but causation is unresolved.

Central adiposity can be clinically relevant even without obvious obesity.

Slide 64 · Core references and source boundaries

Robbins, Cotran & Kumar: Pathologic Basis of Disease, 11th ed. (2026).

Chapter 24, The Endocrine System: Metabolic Defects in Type 2 Diabetes.

Source text: printed pp. 1003–1004; no original chapter PDF or authorized histology images supplied.

Related discussions of monogenic diabetes and complications are separate teaching units.